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Type 2 diabetesA) sequence variation in the segment of the D-loop region encompassing the
initiation sites for replication and transcription was analyzed in the blood of 277 Italian type 2 diabetes
patients and 277 Italian healthy subjects. Compared with the Cambridge Reference Sequence, diabetic
patients show a slightly higher propensity to accumulate base changes in this region, with respect to
controls, although no signiﬁcant association can be established between any of the detected changes and the
diabetic condition. Subjects, patients and controls, harbouring base changes at the replication origins
(positions 57 and 151) and at position 58 were analyzed for mtDNA content. The mtDNA content increased
three–four times only in the diabetic patients bearing the m.151CNT transition, whereas in those bearing the
m.58TNC change the mtDNA content doubled, independently of the afﬁliation haplogroup. This result
suggests that the m.151CNT transition and, to a lower extent, the m.58TNC might confer to the blood cells of
diabetic patients the capability of increasing their mtDNA content, whereas the same transitions have no
effect on control subjects.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Diabetes is a collection of diseases characterized by chronic
hyperglycaemia. It can be classiﬁed into two main groups, insulin-
dependent diabetes mellitus or type 1, at early onset, and non
insulin-dependent diabetes mellitus or type 2, at late onset. While
type 1 diabetes is associated with the autoimmune destruction of
pancreatic β cells, thus producing insulin deﬁciency [1,2], type 2
diabetes, which is the most prevalent form of disease, is due to a
multiplicity of environmental and genetic factors [3,4]. One
particular form of type 2 diabetes is the so-called mitochondrial
diabetes [5], characterized by a maternal transmission together with
a bilateral hearing defect in most of the affected patients. In the large
majority of cases the mitochondrial diabetes is associated with a
m.3243ANG mutation in mtDNA. Also associated with mitochondrial
diabetes is a deletion of 10.4 kb [6]. Following these observations
many other base changes were identiﬁed in diabetic patients;a e Biologia Molecolare, Uni-
y. Tel.: +39 080 5443309; fax:
. Gadaleta).
ll rights reserved.however, the role of such base changes in the development of the
disease is still controversial [7–16].
The sequential accumulation of new mtDNA mutations along
radiating maternal lineages has given rise to haplogroups which tend
to be restricted to speciﬁc geographic areas and/or ethnic groups.
Each haplogroup constitutes a branch or a sub-branch in the
worldwide mtDNA phylogeny and is characterized by a distinguishing
combination of mutations [17]. The preferential association of a
clinical disorder with a speciﬁc haplogroup might suggest that one or
more of the haplogroup-speciﬁc sequence changesmight play a role in
the disease expression [18,19]. However, no evidence of an association
between type 2 diabetes and the major EuropeanmtDNA haplogroups
has been up to now reported [20,21].
In this study the mtDNA sequence variation of a segment of the D-
loop region, never analyzed until now, namely that containing the
initiation sites for mtDNA replication and transcription has been
determined in the total blood of 277 type 2 diabetes patients and 277
healthy subjects. Furthermore, the mtDNA relative content in a subset
of diabetic patients and in one of controls has been measured to verify
the eventual different inﬂuence of some speciﬁc changes on this
relevant parameter. Also the relationship with the haplogroups
afﬁliation has been studied.
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2.1. Subjects
A total of 277 Italian patients with type 2 diabetes (the diagnosis
was made according to the American Diabetes Association criteria),
141 men and 136 women, mean age 63±8 years, were recruited from
the same Italian region (Marche) by the Diabetology Unit, INRCA
Ancona, Italy. 277 Italian subjects in good health (without diabetic
familiarity), 103 men and 174 women, mean age 58±11 years, were
enrolled as a control group. Detailed medical history of all diabetic
patients and controls was recorded. In all subjects antropometric
determinations were performed as well as the following routine
laboratory screening including levels of: fasting plasma glucose, blood
ureic nitrogen, creatinine, lipid proﬁle, reactive protein C, ﬁbrinogen
and counts of red blood cells, white blood cells and platelets. All
patients gave their written informed consent before they enrolled in
the study, which was approved by the local Ethics Committees.2.2. Isolation and ampliﬁcation of DNA
Total DNAwas prepared from peripheral blood using Quiamp DNA
Blood Maxi Kit (Qiagen) and stored at −20 °C. A part of the D-loop
region was ampliﬁed by PCR from total DNA with primers 16.4 For
(16495–16514) -0.6 Rev (609–590). Nucleotide numbering is accord-Fig. 1. Frequencies of control subjects and diabetic patients bearing the reported numbers of
ratio between the number of subjects harbouring a speciﬁc amount of changes and the tot
frequency of diabetic patients harbouring only one mutation and that of controls (⁎pb0.05ing to the Cambridge Reference Sequence (CRS) [22]. The reactionwas
performed as reported in [23]. The ability of the primer pair to amplify
nucleus-embeddedmtDNA pseudogenes was investigated performing
the PCRwith 400ng of total DNAextracted fromhumanosteosarcoma-
derived mtDNA-deﬁcient cell lines (143 B ρ0). Control experiments on
DNA extracted from blood and 143 B ρ+ cells were also performed.
2.3. Sequencing of the D-loop region
To facilitate the direct sequencing of PCR-ampliﬁed products, both
used primers were tagged with M13 sequence as reported in [23]. PCR
products were puriﬁed by using a Quiaquick PCR-puriﬁcation Kit
(QUIAGEN) and sequenced by MWG Biotech facilities. All sequences
were analyzed with Chromas program and compared with the CRS by
means of BLAST program.
2.4. Quantiﬁcation of the mtDNA/nDNA ratio by real-time PCR
The mtDNA content was measured by real-time PCR using an ABI
Prism 7000 real-time PCR (Applied Biosystems). The mtDNA quantity
was referred to the nuclear DNA (nDNA) amount by simultaneous
measurement of the nDNA. The primers for the mtDNA were 3485-
ND1-For (5′-CCCTAAAACCCGCCACATCT-3′) and 3553-ND1-Rev (5′-
TAGAAGAGCGATGGTGAGAGCTAA-3′) and were used together with
the mtDNA probe (5′FAM-CCATCACCCTCTACATCACCGGCC-TAMRA3′)sequence changes in the analyzed segment of the D-loop region. Each frequency was the
al of all analyzed subjects. A statistically signiﬁcant difference was found between the
).
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For (5′-TTAAGGTAGCCAAATGCCTCG-3′) and 28S-7460-Rev (5′-
CCTTGGCTGTGGTTTCGCT-3′) and the 28S rRNA probe was (5′FAM-
TGAACGAGATTCCCACTGTCCCTACCTACTATTC-TAMRA3′) made for nt
7408–7440. The method has been validated by evaluating the equal
reaction efﬁciency of the two amplicons. Each sample was analyzed in
triplicate and in 4–7 different experiments. The PCR was performed
separately for the target ND1 gene and the reference 28S rRNA gene.
The PCR mixture contained the speciﬁc primers (200 nM), speciﬁc
TaqMan probes (100 nM), ∼50–100 ng DNA, 12.5 μl TaqMan Universal
PCR MasterMix (Applied Biosystems, California, USA). Ampliﬁcation
conditions were 50 °C for 2 min to remove carry over by UNG activity,
95 °C for 10 min to inactivate UNG enzyme and activate Taq
Polymerase and 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
The difference in threshold cycle values (ΔCt, namely CtND1−
Ct28SrRNA) was used as a measure of the relative abundance of the
mitochondrial genome. In particular, the mtDNA/nDNA ratio is
reported as 2−ΔCt. To compare the mtDNA amount among diabetic
patients and controls, the control class was taken as a reference
(calibrator) and the number of fold increase of mtDNA content in
diabetics compared to controls was calculated by the following
equation: R=2−ΔCt(diabetics)/2−ΔCt(controls). The standard deviation
of the quotient was calculated as reported in User Bulletin # 2
Applied Biosystems. Data were submitted to t-test to assess
signiﬁcance of the differences observed among groups.Fig. 2. Frequencies of control subjects and diabetic patients bearing each of the speciﬁc base ch
between the number of subjects harbouring the speciﬁc change and the total of all analyzed s
1–3 (CSB1-3), H- and L-strand promoters (HSP and LSP) and TFAM binding sites. Position
Ghivizzani et al. [24]. Base changes, found in two diabetic patients, not previously reported2.5. Statistics
Statistical analysis was carried out by using SPSS Base 11.5
software. Student's t-test and chi square test were used. Statistical
signiﬁcance was set at pb0.05.
3. Results
3.1. Identiﬁcation of sequence variants in the mtDNA D-loop region
To verify whether speciﬁc sequence changes in the segment of the
mtDNA D-loop region, harbouring the initiation sites for replication
and transcription, were associated to type 2 diabetes, we determined
the sequence of part of the D-loop and of the tRNAPhe gene, from
position 16495 to position 609, in the total blood of 277 diabetic
patients and 277 controls, all living in a speciﬁc Italian region,
namely Marche. In order to exclude coampliﬁcation of nuclear
mtDNA pseudogenes, ampliﬁcation experiments were carried out on
DNA extracted from mtDNA-deﬁcient human osteosarcoma-derived
cell lines (143 B ρ0) obtaining no PCR products. Control PCR expe-
riments on DNA extracted from blood and 143 B ρ+ cells were also
performed.
The comparison of the obtained mtDNA sequences with the CRS
[22] shows a variable number of sequence changes (from 0 up to 10)
both in healthy subjects and in diabetic patients. All found sequenceanges found in the analyzed segment of the D-loop region. Each frequency was the ratio
ubjects. The double-headed arrows indicate the localization of Conserved Sequence Box
s of regulatory sequences are from MITOMAP (http://www.mitomap.org), and from
in mtDNA databases are indicated with an asterisk.
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propensity to accumulate changes in the analyzed segment of mtDNA
control region; in fact the number of subjects harbouring a single
change is signiﬁcantly higher in control subjects (n=69) than in
diabetic patients (n=49) (χ2=3.9; pb0.05), whereas the frequen-
cies of subjects harbouring two or three changes are higher in
diabetics than in controls. These last differences do not reach,
however, a statistical signiﬁcance (Fig. 1).
Fig. 2 shows the frequencies of control subjects and diabetic
patients bearing each of the speciﬁc base changes found in the
analyzed segment of the D-loop region. These base changes affected
107 positions out of 685 examined; 29 of them concerned
exclusively diabetic patients, 26 of them control subjects and the
remaining both types of individuals. Two base changes (m.535CNA
and m.589TNC), only found in diabetic patients, were never
reported previously in databases. The position of the sequence
variations in relationship with that of sites critical for the regulation
of mtDNA metabolism (replication origins, Conserved Sequence Box
1–3 (CSB1-3), H- and L-strand promoters (HSP and LSP) and TFAM
binding sites) was analyzed. No association was veriﬁed between
the disease and any of the reported mtDNA base changes in this
group of Italian diabetic patients. Interestingly, we observed
sequence changes at the two H-strand replication origins, that is
at positions 57 and 151 [25] in 3/277 control subjects and in 6/277
diabetic patients.Table 1
mtDNA content and other relevant parameters in subsets of diabetic patients and controls
Sample Sex Age Haplogroup Platelets (103/μl)
C1 M 60 H15 191
C2 M 64 K 180
C3 F 59 T2b 233
Mean
D1 M 67 T2b 189
D2 F 61 T2b 141
D3 F 71 T2b 190
Mean
D4 M 70 T2b 154
D5 F 73 N1b 270
D6 M 77 N1b 132
Mean
D7 M 69 R0a 153
D8 M 66 R0a 216
D9 F 52 R0a 215
Mean
C4 M 58 H 227
C5 M 69 H5 236
C6 F 72 H5 124
C7 M 61 H 166
C8 M 78 H 275
C9 F 55 T2b 384
C10 F 39 T2b 199
C11 F 62 T2b 220
C12 F 46 T2b 236
C13 M 84 N1b 272
C14 F 55 N1b 205
Mean
D10 F 57 T1 195
D11 F 57 R0a 207
D12 M 61 H1 209
D13 M 62 H5 176
D14 F 67 I 239
D15 M 58 T2b 162
D16 F 69 T2b 346
D17 M 57 T2b 256
D18 F 68 T2 284
D19 F 66 T2 291
D20 M 52 T2 203
D21 M 55 T2 187
Mean
⁎ pb0.001=statistically signiﬁcant difference between the sample mean value and the m
replication origins and a speciﬁc change among the nearby ones in the subjects analyzed fo3.2. Determination of the mtDNA content in controls and diabetic
patients containing base changes at the H strand replication origins
or nearby
Since all analyzed patients had a normal peripheral blood cell
number, similar to that of control subjects, a comparison between the
two groups was possible and we tested whether sequence variations
at the mtDNA replication origins or nearby were associated with
differences in the mtDNA content. We determined, by real-time PCR,
the mtDNA content relative to nuclear DNA (nDNA) in the total blood
of the three control subjects and of the six diabetic patients
harbouring changes at the two H-strand replication origins (positions
57 and 151) as well as of 11 controls and 12 diabetic patients not
harbouring such changes. Moreover, the relative content of mtDNA
was measured also in a subset of three diabetic patients harbouring a
base change nearby the replication origin 57, namely at position 58,
which is exclusively present in these three diabetic patients (see
Fig. 2). With the exception of D1, D2 and D3 subjects, all other
individuals analyzed for the mtDNA level were from different
pedigrees.
The sequence changes and the relative mtDNA content together
with the age, the sex, the haplogroup afﬁliation, the amount of
platelets and the glycated haemoglobin (HbA1c) content of each
analyzed individual are reported in Table 1. No correlation between
mtDNA content and age for diabetic patients and controls was foundbearing or not bearing changes at the replication origins or nearby
HbA1c (%) Control region sequence changes mtDNA/nDNA
– 55, 57 1.10±0.15
– 56T, 57, 58+C, 73, 151 1.40±0.15
5.5 73, 151, 152, 309+C 1.27±0.42
1.26±0.32
7.0 55+T, 57, 59, 73, 151, 152, 309+2C 4.20±0.42
6.6 55+T, 57, 59, 73, 151, 152, 309+2C 3.50±0.90
7.4 55+T, 57, 59, 73, 151, 152, 309+2C 3.40±0.80
3.80±0.76⁎
6.8 73,150, 151, 309+C, 573+2C 3.35±0.49
7.7 73, 151, 152, 200, 309+C 3.90±0.94
11.5 73, 151, 152, 200, 309+C 3.36±0.75
3.54±0.64⁎
5.5 58, 60+T, 64, 309+C 1.95±0.06
8.6 58, 60+T, 64, 309+C 2.00±0.27
8.2 58, 60+T, 64, 309+C 2.50±0.51
2.16±0.41⁎
5.9 309+2C 0.97±0.15
5.5 152, 456 1.00±0.10
6.6 146, 456 1.03±0.10
5.4 146, 195 0.97±0.15
6.4 – 1.00±0.10
6.1 73 0.97±0.23
5.6 73 0.81±0.33
5.7 73 0.92±0.23
6.5 73 1.27±0.57
5.5 73, 152, 200, 309+C,522delCA 1.49±0.37
5.7 73, 152, 338, 522delCA 1.25±0.12
1.05±0.29
8.0 73, 152, 309+C, 456 0.99±0.21
7.4 60+T, 64, 72G 0.80±0.05
6.7 195 1.25±0.31
7.8 204, 456 0.96±0.18
6.5 73, 199, 204, 250 0.71±0.13
6.4 73 1.80±0.14
8.2 73, 309+C 1.15±0.21
8.6 73 1.10±0.10
8.0 73, 146,309+C, 522delCA 0.91±0.20
7.3 73, 309+C 1.77±0.30
9.0 73, 146, 309+C 1.07±0.40
7.1 73, 146,309+C, 522delCA 1.85±0.63
1.19±0.39
ean value of control class (C4–C14). Indicated in bold are the sequence changes at the
r mtDNA content. HbA1c (%)=percentage of glycated haemoglobin.
551A. Cormio et al. / Biochimica et Biophysica Acta 1787 (2009) 547–552in our analyzed subjects. ThemtDNA content of the subset of the three
healthy individuals (C1–C3) bearing the m.57TNC and/or the
m.151CNT transitions was unchanged when compared with that of
the 11 age-matched controls (C4–C14) not bearing base changes at the
replication origins. The subsets of the six diabetic patients constituted
by three patients (D1–D3) presenting the m.57TNC and the m.151CNT
and three patients (D4–D6) with the m.151CNT change alone showed
a three–four-fold increase of mtDNA content compared with age-
matched controls (C4–C14) and diabetic patients (D10–D21) without
the above-reported base changes. The transition at position 57 does
not seem to inﬂuence the mtDNA content since the increase of mtDNA
content was the same in D1–D3 (bearing them. 57TNC transition) and
in D4–D6 patients (not bearing the m. 57TNC transition). As far as the
three patients D7–D9 with the m.58TNC change, their content of
mtDNA was only doubled compared with age-matched controls (C4–
C14) and diabetic patients (D10–D21) without this change. No
relationship was found between the mtDNA content and the
haplogroup to which the analyzed subjects belong; in fact, patients
D1–D6, exhibiting the highest contents of mtDNA, belong to the same
haplogroups (T2b and N1b) of the control C3, bearing the m.151CNT
transition, of the D15–D17 diabetic patients and of the C9–C14 control
subjects not bearing any of the above reported base changes and all
having the same mtDNA content.
4. Discussion
The present study about type 2 diabetes and mtDNA sequence
variation in the segment of D-loop region containing the transcription
and replication origins deals with a large size of sampled individuals
(277 diabetics and 277 controls), highly homogeneous as geographi-
cal and population origin. They have all been recruited, in fact, in the
same Marche region of the Italian peninsula. The analyzed segment of
mtDNA has never been studied until now. The results about the base
changes in this mtDNA segment show that diabetic individuals have a
slightly higher propensity to accumulate mutations in their mtDNA.
Consistent conclusions were obtained by Sherrat et al. [26] who
analyzed the sequence of another segment of the D-loop region in a
smaller number of individuals. However, no association was veriﬁed
between the disease and any of the reported mtDNA base changes in
this group of Italian diabetic patients as other authors did analyzing
different regions of mtDNA and groups of subjects with distinct
geographical origins [14,16]. Our analysis of the pattern of nucleotide
substitutions in control and diabetic individuals shows that the most
frequent substitutions are A–G and T–C (about 65% of the total
mutations), while C–T and G–A account only for 30%. This result
supports the previously reported hypothesis [27] that the majority of
mtDNA mutations derive from errors of the gamma-DNA polymerase
activity due to the uneven composition of the mitochondrial
deoxynucleotide pool. The data reported here do not conﬁrm those
by Kamiya and Aoki [28] who, by studying a small population (six
diabetics and six controls), found an incidence of somatic transversion
mutations signiﬁcantly higher in diabetic patients than in controls.
A relevant result of this study concerns the mtDNA content in a
subset of diabetic patients harbouring the m.151CNT and/or the
m.57TNC or the m.58TNC transitions (9/277 patients). In fact, only
these diabetic patients (D1–D9, see Table 1) present a statistically
signiﬁcant increase of the mtDNA content in blood with respect to a
similar number (12/277) of other patients not harbouring the same
base changes and featuring an unchanged mtDNA content (D10–D21,
see Table 1). The mtDNA content in the blood of the diabetic patients
D1–D9 is remarkably increased also with respect to control subjects
with or without these changes (C1–C3 and C4–C14, respectively, see
Table 1). Such data strongly suggest only in diabetic patients some
kind of association between the presence of one of these transitions
(the m.151CNT or the m.58TNC) and the increase of mtDNA content.
The highest increase (three–four times) of mtDNA content was foundin those patients having the m.151CNT transition (D1–D6). In the
diabetic patients analyzed here the increase of mtDNA content did not
appear to be associated with a speciﬁc haplogroup.
According to the asymmetric model of mtDNA replication [29] and
to Fish et al. [25], as for the human mtDNA synthesis, the major
replication origin of mtDNA is position 57 which is mainly responsible
for mtDNA maintenance under steady-state conditions, whereas
position 151 may be more important in the replication of mtDNA
during the recovery after mtDNA depletion. In this study the m.57TNC
transition does not inﬂuence the mtDNA content, whereas the
m.151CNT transition and, to a lower extent, the m.58TNC transition
seem to confer to blood cells of diabetic patients the capability of
increasing their mtDNA content, probably as an adaptation to the
disease-related oxidative stress [30,31]. Many published reports
associate an increase of mtDNA copy number to an oxidative stress
situation: in aging or/and smoking cigarettes individuals [32], in
cultured human lung ﬁbroblasts exposed to H2O2 [33], in human
leucocytes from different age groups [34]. Using cell lines carrying
different common mouse mtDNA haplotypes in an identical nuclear
background, Moreno-Loshuertos et al. [35] showed that different
amounts of ROS are associated to different mtDNA variants and that
cells producing more ROS have higher mtDNA copy numbers as a
consequence of compensatory mechanisms triggered by ROS.
The detailed mechanism which regulates mtDNA copy number in
animal cells remains unclear [36,37]. The diabetes-associated oxida-
tive stress in subjects carrying the here described mtDNA base
changes might constitute another experimental model to dissect the
problem.
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